M&A / Deals Parexel buys Vitrana to boost patient safety toolkit PharmaphorumContract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum.Read full story pharminent April 30, 2026 (Last updated: May 1, 2026) Pharmaphorum Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed sum. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapyNext: Merck still sees ‘compelling’ outlook for Terns leukemia drug Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
